Market Optimizer

Schizophrenia Companies & Drugs Pipeline Industry Review H2 2014 adds “Schizophrenia – Pipeline Review, H2 2014” report to its research database. The report provides an overview of the Schizophrenia’s therapeutic pipeline.


Dallas, TX -- (SBWIRE) -- 11/05/2014 -- This report provides comprehensive information on the therapeutic development for Schizophrenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Schizophrenia and special features on late-stage and discontinued projects.

Schizophrenia is a mental disorder often characterized by abnormal social behavior and failure to recognize what is real. Common symptoms include false beliefs, unclear or confused thinking, auditory hallucinations, reduced social engagement and emotional expression, and inactivity. Diagnosis is based on observed behavior and the person's reported experiences.

Complete Report Available

The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Schizophrenia - Companies Involved in Therapeutics Development:

AbbVie Inc., Acadia Pharmaceuticals Inc., Adamed Sp. z o.o., Addex Therapeutics Ltd, Aestus Therapeutics, Inc., AGY Therapeutics, Inc., Alkermes Plc, Amgen Inc., Angita B.V., Ascendis Pharma A/S, Astellas Pharma Inc., Athersys, Inc., BioCrea GmbH, Biotie Therapies Corp., Boehringer Ingelheim GmbH, BRAINco Biopharma, S.L., Cerecor Inc., Critical Pharmaceuticals Limited, Curemark, LLC, Delpor, Inc., Domain Therapeutics SA, Dong Wha Pharma Co., Ltd., Echo Pharmaceuticals B.V., Egis Gyogyszergyar Nyrt, Eli Lilly and Company, Evotec AG, F. Hoffmann-La Roche Ltd., FORUM Pharmaceuticals Inc., Galenea Corp., GeNeuro SA, Genovate Biotechnology Co., LTD., Gilead Sciences, Inc., Glenmark Pharmaceuticals Ltd., GP Pharm, S.A., GW Pharmaceuticals plc, H. Lundbeck A/S, Heptares Therapeutics Ltd., Hisamitsu Pharmaceutical Co., Inc., Intra-Cellular Therapies, Inc., Jiangsu Hansoh Pharmaceutical Co., Ltd., Jiangsu Nhwa Pharma Corporation, Johnson & Johnson, Karuna Pharmaceuticals Inc., KemPharm, Inc., Laboratorios Farmaceuticos Rovi, S.A., Lead Discovery Center GmbH, Luye Pharma Group Ltd., MarcoPolo Pharmaceuticals SA, Merck & Co., Inc., Mithridion, Inc., Mitsubishi Tanabe Pharma Corporation, Naurex, Inc., Neurocrine Biosciences, Inc., NeurOp, Inc, Newron Pharmaceuticals S.p.A., Novartis AG, Nuvo Research Inc., Omeros Corporation, Otsuka Holdings Co., Ltd, Peptron, Inc., Pfizer Inc., Promentis Pharmaceuticals, Inc., Reckitt Benckiser Pharmaceutical, Inc., Reviva Pharmaceuticals Inc, Richter Gedeon Nyrt., Rottapharm SpA, SK Biopharmaceuticals Co., Ltd., SK Chemicals Co., Ltd, Sumitomo Dainippon Pharma Co., Ltd, Sunovion Pharmaceuticals Inc., Suven Life Sciences Ltd., Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Targacept, Inc., Tetra Discovery Partners LLC, Teva Pharmaceutical Industries Limited, Vanda Pharmaceuticals Inc., XTL Biopharmaceuticals Ltd., Zogenix, Inc., Zysis Limited.

Order a Purchase copy


-The report provides a snapshot of the global therapeutic landscape of Schizophrenia

-The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

-The report reviews key players involved in the therapeutics development for Schizophrenia and enlists all their major and minor projects

-The report summarizes all the dormant and discontinued pipeline projects

-A review of the Schizophrenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

-Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

-A detailed assessment of monotherapy and combination therapy pipeline projects

-Coverage of the Schizophrenia pipeline on the basis of target, MoA, route of administration and molecule type

-Latest news and deals relating related to pipeline products

Reasons to buy:

-Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

-Develop strategic initiatives by understanding the focus areas of leading companies

-Identify and understand important and diverse types of therapeutics under development for Schizophrenia

-Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

-Devise corrective measures for pipeline projects by understanding Schizophrenia pipeline depth and focus of Indication therapeutics

-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

-Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Browse more reports on Neurology therapeutics Market